Company profile
LANTERN PHARMA INC.
NASDAQ:LTRNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZIRDAFULVEN | phase1_2 | — | 1 | active |
| ZIRDAFULVEN, (S)- | phase1 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05456256 | phase2 | recruiting | 2023-03-01 | 2026-12-01 | Lantern Pharma Inc. | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma |
| NCT06132503 | phase1 | recruiting | 2023-01-03 | 2028-11-30 | Lantern Pharma Inc. | Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors |
| NCT05933265 | phase1_2 | active_not_recruiting | 2023-06-09 | 2026-07-28 | Lantern Pharma Inc. | Study of LP-184 in Patients With Advanced Solid Tumors |
FDA applications (0)
No records yet.